NASDAQ:INGNInogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INGN stock has decreased by 12.3% and is now trading at $35.61. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Inogen.

Inogen will be holding an earnings conference call on Tuesday, August 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Inogen Inc (NASDAQ:INGN) issued its quarterly earnings results on Tuesday, May, 5th. The medical technology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.04. The medical technology company earned $88.49 million during the quarter, compared to analyst estimates of $82.33 million. Inogen had a return on equity of 4.93% and a net margin of 3.90%. The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.24 earnings per share. View Inogen's earnings history.

7 brokers have issued 12-month price targets for Inogen's shares. Their forecasts range from $45.00 to $80.00. On average, they expect Inogen's stock price to reach $60.80 in the next year. This suggests a possible upside of 70.7% from the stock's current price. View analysts' price targets for Inogen.

News headlines about INGN stock have trended very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Inogen.

Inogen saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 2,560,000 shares, a decrease of 9.5% from the June 15th total of 2,830,000 shares. Based on an average trading volume of 391,100 shares, the days-to-cover ratio is currently 6.5 days. Approximately 14.0% of the shares of the company are short sold. View Inogen's Current Options Chain.

Some companies that are related to Inogen include Avanos Medical (AVNS), Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Histogenics (HSGX), Precision Therapeutics (POAI), Rewalk Robotics (RWLK), Ocugen (OCGN), NanoVibronix (NAOV) and Bionik Laboratories (BNKL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Intel (INTC) and Advanced Micro Devices (AMD).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.19%) and Envestnet Asset Management Inc. (0.04%). Company insiders that own Inogen stock include Brenton Taylor, Byron Myers, Heath Lukatch, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC. View insider buying and selling activity for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland. View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $35.61.

Inogen has a market capitalization of $785.20 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

The official website for Inogen is www.inogen.com.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]